Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches Marcel O. Bonn-Miller, Mahmoud A. ElSohly, Mallory J. E. Loflin, Suman Chandra and Ryan Vandrey International Review of Psychiatry, 2018, VOL. 30, NO. 3, 277–284 Doi : 10.1080/09540261.2018.1474730 ABSTRACT Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical [...]
Lire la suiteA cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis Mallory J E Loflin, Kimberly Babson, James Sottile, Sonya B Norman, Staci Gruber, and Marcel O Bonn-Miller The American Journal of Drug and Alcohol Abuse, 2019, VOL. 45, NO. 5, 506–513. Doi : 10.1080/00952990.2019.1604722 ABSTRACT Background : With a rise in public pressure to increase veteran access to medicinal cannabis, free cannabis collectives for military veterans are proliferating across the US. Objectives : The aim of the current study was to document which cannabis formulations and routes of administration are chosen by veterans with increased access to cannabis, and to determine [...]
Lire la suiteCannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users Katherine A. Belendiuk, Kimberly A. Babson, Ryan Vandrey, Marcel O. Bonn-Miller Addictive Behaviors, 2015, 50, 178–181 doi : 10.1016/j.addbeh.2015.06.032 a b s t r a c t Introduction : Individuals report using cannabis for the promotion of sleep, and the effects of cannabis on sleep may vary by cannabis species. Little research has documented preferences for particular cannabis types or cannabinoid concentrations as a function of use for sleep disturbances. Methods : 163 adults purchasing medical cannabis for a physical or mental health condition at a cannabis dispensary were recruited. They provided self-report of (a)whether [...]
Lire la suiteTherapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis Tibor M. Brunt, Marianne van Genugten, Kathrin Honer-Snoeken, Marco J. van de Velde, and Raymond J.M. Niesink Journal of Clinical Psychopharmacoly, 2014, 34, 344Y349 Doi : 10.1097/JCP.0000000000000129 Abstract : In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special [...]
Lire la suiteL’huile de chanvre contient-elle du THC et du CBD ? Newsweed, 11 février 2020 Aurélien BERNARD https://www.newsweed.fr/huile-chanvre-contient-thc-cbd/ L’huile de chanvre, extraite des graines, est une source précieuse d’omega 3 et 6 et de nutriments dans l’alimentation quotidienne. Sa valeur nutritionnelle et thérapeutique pourrait néanmoins aussi être attribuée à sa composition en cannabinoïdes qui, si faiblement présents, existent quand même. Dans une étude de 2019, plusieurs cannabinoïdes ont été détectés dans l’huile de graines de chanvre et permettent de déterminer des différences dans leur composition chimique. Bien que le CBDA et le CBD soient prédominants dans les dix huiles étudiées, 20 autres cannabinoïdes «mineurs» ont été [...]
Lire la suiteOlivier Véran pour l’extension de l’expérimentation du cannabis médical à la Polynésie française Newsweed, 18 février 2020 Aurélien BERNARD Olivier Véran, nommé ministre de la Santé ce week-end en remplacement d’Agnès Buzyn, n’aura pas besoin d’être mis dans le bain pour reprendre le dossier du cannabis thérapeutique en France. Ce dernier a en effet porté le projet d’expérimentation du cannabis médical et est à l’origine du passage de son amendement dans la loi de Finances 2020. En réponse à une question de son ancien collègue député polynésien, Moetai Brotherson, qui l’interrogeait sur la possibilité d’étendre l’expérimentation métropolitaine du cannabis médical à la Polynésie française, [...]
Lire la suiteCannabis Business France, les 4 et 5 mai 2020 Newsweed, 19 février 2020Par Aurélien BERNARD https://www.newsweed.fr/cannabis-business-france-4-5-mai-2020/ L’industrie du cannabis et du chanvre se réunira à Paris les 4 et 5 mai 2020 pour façonner l’avenir du marché français. Pour sa deuxième édition, Cannabis Business France 2020 se déroulera dans un contexte mouvant. Alors que la France débutera un programme pilote de cannabis médical de deux ans, cette plateforme d’échange unique vise à rassembler les principaux chefs d’entreprise pour discuter des derniers développements des marchés français du chanvre et du cannabis médical. Le Dr Pascal Douek et le Dr Alexandre Maciuk, tous deux membres du comité [...]
Lire la suiteComprehensive classification of USA cannabis samples based on chemical profiles of major cannabinoids and terpenoids Ramia Z. Al Bakain, Yahya S. Al-Degs, James V. Cizdziel and Mahmoud A. Elsohly Journal of Liquid Chromatography & Related Technologies, 2019 Doi : 10.1080/10826076.2019.1701015 ABSTRACT Different USA-origin cannabis samples were analyzed by GC-FID to quantify all possible cannabinoids and terpenoids prior to their clustering. Chromatographic analysis confirmed the presence of seven cannabinoids and sixteen terpenoids with variable levels. Among tested cannabinoids, D9-Tetrahydro-cannabinol D9-THC and cannabinol CBN were available in excess amounts (1.2–8.0 wt%) and (0.22–1.1 wt%), respectively. Fenchol was the most abundant terpenoid with a range of (0.03–1.0 wt%). [...]
Lire la suiteA novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports | (2019) 9:20335 | www.nature.com/scientificreports Doi : 10.1038/s41598-019-56785-1 (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC [...]
Lire la suiteIsolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa Mohamed M. Radwan, Mahmoud A. ElSohly, Abir T. El-Alfy, Safwat A. Ahmed, Desmond Slade, Afeef S. Husni, Susan P. Manly, Lisa Wilson, Suzanne Seale, Stephen J. Cutler, and Samir A. Ross Journal of Natural Products, 2015 June 26, 78, (6), 1271–1276. doi : 10.1021/acs.jnatprod.5b00065 Abstract Seven new naturally occurring hydroxylated cannabinoids (1–7), along with the known cannabiripsol (8), have been isolated from the aerial parts of high-potency Cannabis sativa. The structures of the new compounds were determined by 1D and 2D NMR spectroscopic analysis, GC-MS, and HRESIMS as 8α hydroxy-Δ9-tetrahydrocannabinol (1), 8β-hydroxy-Δ9-tetrahydrocannabinol (2), 10α-hydroxy-Δ8 [...]
Lire la suite